Heartflow (NASDAQ:HTFL) Reaches New 12-Month Low – Time to Sell?

Shares of Heartflow, Inc. (NASDAQ:HTFL) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $25.59 and last traded at $25.83, with a volume of 263480 shares changing hands. The stock had previously closed at $26.48.

Analyst Upgrades and Downgrades

HTFL has been the topic of a number of analyst reports. Zacks Research raised Heartflow to a “hold” rating in a research report on Wednesday, September 3rd. Piper Sandler began coverage on Heartflow in a report on Tuesday, September 2nd. They issued an “overweight” rating and a $38.00 target price on the stock. JPMorgan Chase & Co. raised their price target on Heartflow from $36.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Stifel Nicolaus upped their price target on shares of Heartflow from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Finally, Morgan Stanley started coverage on Heartflow in a research report on Tuesday, September 2nd. They issued an “equal weight” rating and a $35.00 price objective on the stock. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $38.60.

Heartflow Price Performance

The firm’s fifty day simple moving average is $32.25.

Heartflow (NASDAQ:HTFL) last posted its quarterly earnings data on Friday, September 19th. The company reported ($1.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($1.26). The company had revenue of $43.42 million during the quarter, compared to the consensus estimate of $43.20 million.

Institutional Trading of Heartflow

Several large investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP purchased a new stake in Heartflow during the third quarter valued at approximately $164,263,000. Baillie Gifford & Co. bought a new stake in shares of Heartflow during the 3rd quarter valued at $101,182,000. Schusterman Interests LLC purchased a new stake in shares of Heartflow in the 3rd quarter worth $65,274,000. Vanguard Group Inc. bought a new position in Heartflow in the 3rd quarter worth $48,871,000. Finally, Capital International Investors purchased a new position in Heartflow during the third quarter valued at $43,671,000.

Heartflow Company Profile

We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of March 31, 2025, our Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone.